Intravacc is an established independent CDMO with years of experience in developing and optimizing vaccines for infectious diseases and therapeutic vaccines, which has transferred its technology worldwide for vaccines against polio, measles, diphtheria, Hib, and influenza. Around 30% of childhood disease vaccines are based on Intravacc’s technology and knowhow. Intravacc offers a wide range of expertise for independent vaccine development, from concept to Phase I/II clinical studies, for customers around the world. Intravacc continues to capitalize on the critical global trends in healthcare: the ever-growing need for prevention and intervention for infectious diseases and cancer. Our innovative vaccine platforms and vaccine contract development and manufacturing capabilities are well positioned to address the unmet needs in the vaccine and immune therapy market which is currently estimated at $37 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% to $55 billion by 2027. The company’s head office is located on the Utrecht Science Park location Bilthoven, The Netherlands, and has state-of-the-art laboratories and GMP production facilities. Intravacc B.V. is a limited liability company incorporated under Dutch law. Intravacc is a state holding company since 1 January 2021, under the Ministry of Health, Welfare and Sports (VWS). | . | Your specialized CDMO to accelerate the development of your viral, bacterial, therapeutic, and conjugate vaccines. From discovery to phase II clinical trial. Based in the Netherlands within the Utrecht Science Park in Bilthoven, Intravacc is a globally recognized pioneer and leader in translational vaccinology. With decades of experience, we stand as an independent Contract Development and Manufacturing Organization (CDMO) within the vaccine industry. Our purpose is to serve as the vital link between your discoveries and early-stage clinical trials of new vaccines. We understand that this journey from concept to GMP production is often riddled with challenges, and we specialize in mitigating risks and reducing costs. | Your specialized CDMO for viral, bacterial, therapeutic, and conjugate vaccines Based in the Netherlands and nestled within the Utrecht Science Park in Bilthoven, Intravacc is a globally recognized leader in translational vaccinology. With decades of experience, we stand as an independent Contract Development and Manufacturing Organization (CDMO) within the vaccine industry. Our purpose is to serve as the vital link between your discoveries and early-stage clinical trials. We understand that this journey from concept to GMP production is often riddled with challenges, and we specialize in mitigating risks and reducing costs. The entire team at Intravacc is committed to blazing new paths in vaccine development. We have an exceptional track record imagining and realizing technologies that enable tomorrow’s vaccines. That expertise in vaccine development is at the core of our CDMO services and candidate vaccines out-licensing.
HitGen
HitGen Inc. (SSE: 688222.SH), founded in 2012, is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen is committed to building a world-class innovative biopharmaceutical enterprise and contributing to the better life and health of mankind. Engaged in the discovery and optimization of small molecules and nucleic acid drugs, HitGen dedicates itself to cultivating an internationally leading drug discovery and optimization system centered on four key technology platforms, including DNA-encoded library technology (including DEL design, synthesis and screening, and application expansion), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). It provides new molecular entities (NMEs) at different stages of research and development for the pharmaceutical industry, through its diversified business models including research and development services, out-licensing of projects at different R&D stages, and new drug launches in the long term, with an aim to address unmet clinical needs with innovative therapeutic solutions. As a leader in the field of DEL technology, HitGen has been committed to the development, application and improvement of DEL technology since its establishment. By June 30, 2022, HitGen’s DELs contains more than 1.2 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many thousands of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets. Through systematic DEL compound design, HitGen DELs has involved the use of more than 6000 different types of chemical scaffolds, which includes most of the core scaffolds of currently approved small-molecule drugs and many privileged scaffolds of small-molecules in clinical trials, and the approximately 40,000 different building blocks. HitGen has approximately 20 in-house drug discovery projects at different stages of research and development, among which 4 have obtained IND approvals and entered into clinical trials. HitGen is in collaboration with pharmaceutical, biotech and chemical companies, foundations and research institutes in the Americas, Asia, Europe, Africa, and Oceania. For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com. For business development: bd@hitgen.com | HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage. | About HitGen Inc. HitGen Inc. (SSE: 688222.SH), is a drug discovery research company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid-based drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Meanwhile, we are developing a DEL+AI+ Automated DMTA (Design-Make-Test-Analyze) molecular optimization platform to accelerate the discovery and optimization process of preclinical candidate compounds. Through our diverse and flexible business models, we have built up collaboration partnerships with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.
HIPRA Biotech Services
HIPRA Biotech Services is a CDMO supporting pharmaceutical and biotech companies across the full early clinical to commercial lifecycle of biologic and vaccine products. Backed by over 50 years of scientific and technical excellence including our internally commercialized and marketed COVID vaccine, we offer end-to-end development and GMP manufacturing solutions across a wide range of expression platforms, from viral to mammalian to microbial platforms, to make clinical and commercial drug substance and drug product for our clients. With a team of 450+ R&D scientists and over 1,000+ professionals in Manufacturing, QA and QC, state-of-the-art facilities, and a strong regulatory track record, we deliver both clinical and commercial programs with speed, quality, and flexibility. We continuously invest in innovation and capacity expansion, making us a trusted partner that will grow with our clients for their long-term success. https://www.hipra.com/en/cdmo-services
HANS Scientific
HANS Scientific is your nimble partner for CMO and WFI Generation. Our on-staff engineering and regulatory teams enable us to ramp projects quickly and with flexibility to meet your requirements. We are an agile, US-Based CMO with aseptic Fill/Finish and ALUS Lyophilization chamber. Highly innovative WFI generation equipment designed/built in the US, and bulk WFI in Bioprocess containers are readily available.
Groupe PARIMA
Groupe PARIMA is a Contract Development and Manufacturing Organization (CDMO), established in 1994. Over the years, we have developed an expertise in the development and manufacturing of non-sterile liquids, suspensions, and semi-solid drug products. This strategic focus has allowed us to establish a unique expertise to support your product development and manufacturing needs, which, combined to our operational flexibility and commitment to delivering on time, enables us to operate as an extension of your team. Our business is 100% fee-for-service and exclusively focused on contract services. We are here to help you meet your company objectives, not to compete with you. | Groupe PARIMA is a leading Contract Development & Manufacturing Organization (CDMO) that excels in the development and manufacturing of non-sterile pharmaceutical products. Specializing in liquids, semi-solids, and suspensions, we offer an extensive range of services focused on product development, commercial manufacturing, packaging and laboratory testing. Our modern facility is equipped to handle complex pharmaceutical formulations and packaging requirements. At the core of our operation is a deep commitment to research and development. Our expert team collaborates closely with clients to design and optimize formulations that meet specific patient needs, ensuring each product achieves optimal effectiveness and regulatory approval. This focus on development is complemented by our flexibility to scale processes seamlessly from pilot batches to clinical supply and eventually large-scale commercial production. Our team of skilled professionals bring a wealth of industry knowledge and technical expertise, making us a preferred partner for both emerging biotechs and established pharmaceutical companies across 28 countries. Groupe PARIMA’s ability to adapt swiftly to changing market conditions and client requirements sets us apart in the dynamic pharmaceutical landscape. With ample manufacturing capacity and comprehensive on-site services including laboratory testing and regulatory compliance activities, we are equipped to handle diverse project demands with precision. Whether advancing a novel treatment or expanding production capabilities, Groupe PARIMA provides the expertise and infrastructure necessary to bring your pharmaceutical products to global markets. Explore the possibilities with Groupe PARIMA as your dedicated CDMO partner. Discover our full range of development capabilities and services at www.groupeparima.com. | Groupe PARIMA, a CDMO since 1994, specializes in the development and manufacturing of non-sterile liquids, suspensions, and semi-solids. With deep expertise in complex formulations, scale-up, and regulatory compliance, we provide end-to-end support from development to commercial production. Our flexible approach, technical proficiency, and commitment to on-time delivery make us a trusted partner for pharmaceutical companies worldwide. As a dedicated contract service provider, we focus entirely on supporting our clients’ success with tailored solutions and operational agility.
Fluid Air
Established in 1983, Fluid Air serves companies that manufacture powdered products and ingredients, in industries including biopharmaceutical, advanced batteries, nutraceutical, food, fine chemicals, and agriculture. Our PolarDry® electrostatic drying system allows customers to bypass the inherent constraints of freeze drying and conventional spray drying, achieving scalable production and lower costs. Learn more about Fluid Air at www.fluidairinc.com.
eXmoor Pharma
eXmoor is a full service Cell & Gene Therapy CDMO with a difference. We are backed by 20 years CMC consultancy experience, supporting over 150 organisations to accelerate novel therapies from discovery to patients. We provide expert solutions at all stages of the development journey from early process development and scale-up through to GMP manufacture, fill and finish and QP release. We are open, transparent and will work with you at every step to de-risk and streamline your project and maximise the chances of product success. | eXmoor Pharma is a full-service Cell & Gene Therapy CDMO with a difference. Backed by over 20 years of consultancy experience, we’ve helped more than 170 organisations accelerate therapies from discovery to delivery. We deliver more than manufacturing. Our integrated consultancy and technical development services span the full journey from early-phase strategy to GMP manufacturing and commercialisation. Our in-house experts work as an extension of your team, helping you plan, scale, and deliver therapies that are clinically and commercially viable. We bring deep domain knowledge across process development, analytical science, facility design, GMP production, and regulatory strategy. With a purpose-built facility and a commitment to full IP freedom, we give innovators the space and flexibility to focus on what matters most: getting life-changing treatments to patients faster.
ExcellGene
ExcellGene is a leading biotechnology company specializing in developing and producing high-quality recombinant proteins and monoclonal antibodies, with expertise in CHO and HEK-293 cell lines. With over 20 years of experience in the field, our dedicated team of experts ensures reliable, timely, and efficient customized solutions meeting the highest quality standards for a wide range of research, diagnostic, and therapeutic applications. Visit our booth #1743 to learn more about our services and products, and go to www.excellgene.com for additional information or to get in touch. | ExcellGene is a leading biotechnology company specializing in developing and producing high-quality recombinant proteins and monoclonal antibodies, with expertise in CHO and HEK-293 cell lines. With over 20 years of experience in the field, our dedicated team of experts ensures reliable, timely, and efficient customized solutions meeting the highest quality standards for a wide range of research, diagnostic, and therapeutic applications. | Looking for a trusted partner in the development of cell lines and manufacturing processes? Look no further. With over 20 years of experience, we specialize in high-yielding (5-14 g/L), GMP-ready, CHO, and HEK293 cell lines for the production of biologics, biosimilars, and gene therapy (AAV, Adenovirus). We have a proven track record of expressing all types of proteins, including bi-specific mAb, Fc-fusions, viral proteins, cytokines, and more. Our team of scientists is ready to support your project from start to finish, including process development, analytical methods, scale-up, tox-batches, and Master Cell Banking. At our company, we pride ourselves on our commitment to quality and customer satisfaction. Contact us today to see how we can help you achieve your goals and be your trusted partner in cell line and process development.